Yukihide Momozawa1, Yusuke Iwasaki1, Makoto Hirata2,3, Xiaoxi Liu1, Yoichiro Kamatani4, Atsushi Takahashi4,5, Kokichi Sugano2,6, Teruhiko Yoshida2, Yoshinori Murakami7, Koichi Matsuda8, Hidewaki Nakagawa9, Amanda B Spurdle10, Michiaki Kubo11. 1. Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa, Japan. 2. Department of Genetic Medicine and Services, National Cancer Centre Hospital, Chuo-ku, Tokyo, Japan. 3. Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan. 4. Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa, Japan. 5. Department of Genomic Medicine, Research Institute, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan. 6. Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Centre Research Institute, Yohnan, Tochigi, Japan. 7. Division of Molecular Pathology, Department of Cancer Biology, Institute of Medical Science. 8. Graduate School of Frontier Sciences, Minato-ku, Tokyo, Japan. 9. The University of Tokyo, Minato-ku, Tokyo, Japan; Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Minato-ku, Tokyo, Japan. 10. Division of Genetics and Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Herston, Queensland, Australia. 11. RIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa, Japan.
Abstract
BACKGROUND: Genetic testing has been conducted in patients with prostate cancer (PCa) using multigene panels, but no centralized guidelines for genetic testing exist. To overcome this limitation, we investigated the demographic and clinical characteristics of patients with pathogenic variants. METHODS: We sequenced eight genes associated with hereditary PCa in 7636 unselected Japanese patients with PCa and 12 366 male, cancer-free control individuals. We assigned clinical significance for all 1456 variants using the American College of Medical Genetics and Genomics guidelines and ClinVar. We compared the frequency of carriers bearing pathogenic variants between cases and control participants with calculated PCa risk in each gene and documented the demographic and clinical characteristics of patients bearing pathogenic variants. All statistical tests were two-sided. RESULTS: We identified 136 pathogenic variants, and 2.9% of patients and 0.8% of control individuals had a pathogenic variant. Association with PCa risk was statistically significant for variants in BRCA2 (P < .001, odds ratio [OR] = 5.65, 95% confidence interval [CI] = 3.55 to 9.32), HOXB13 (P < .001, OR = 4.73, 95% CI = 2.84 to 8.19), and ATM (P < .001, OR = 2.86, 95% CI = 1.63 to 5.15). We detected recurrent new pathogenic variants such as p.Gly132Glu of HOXB13. Patients with pathogenic variants were 2.0 years younger at diagnosis and more often had smoking and alcohol drinking histories as well as family histories of breast, pancreatic, lung, and liver cancers. CONCLUSIONS: This largest sequencing study of PCa heredity provides additional evidence supporting the latest consensus among clinicians for developing genetic testing guidelines for PCa.
BACKGROUND: Genetic testing has been conducted in patients with prostate cancer (PCa) using multigene panels, but no centralized guidelines for genetic testing exist. To overcome this limitation, we investigated the demographic and clinical characteristics of patients with pathogenic variants. METHODS: We sequenced eight genes associated with hereditary PCa in 7636 unselected Japanese patients with PCa and 12 366 male, cancer-free control individuals. We assigned clinical significance for all 1456 variants using the American College of Medical Genetics and Genomics guidelines and ClinVar. We compared the frequency of carriers bearing pathogenic variants between cases and control participants with calculated PCa risk in each gene and documented the demographic and clinical characteristics of patients bearing pathogenic variants. All statistical tests were two-sided. RESULTS: We identified 136 pathogenic variants, and 2.9% of patients and 0.8% of control individuals had a pathogenic variant. Association with PCa risk was statistically significant for variants in BRCA2 (P < .001, odds ratio [OR] = 5.65, 95% confidence interval [CI] = 3.55 to 9.32), HOXB13 (P < .001, OR = 4.73, 95% CI = 2.84 to 8.19), and ATM (P < .001, OR = 2.86, 95% CI = 1.63 to 5.15). We detected recurrent new pathogenic variants such as p.Gly132Glu of HOXB13. Patients with pathogenic variants were 2.0 years younger at diagnosis and more often had smoking and alcohol drinking histories as well as family histories of breast, pancreatic, lung, and liver cancers. CONCLUSIONS: This largest sequencing study of PCa heredity provides additional evidence supporting the latest consensus among clinicians for developing genetic testing guidelines for PCa.
Authors: Jianfeng Xu; W Kyle Resurreccion; Zhuqing Shi; Jun Wei; Chi-Hsiung Wang; S Lilly Zheng; Peter J Hulick; Ashley E Ross; Christian P Pavlovich; Brian T Helfand; William B Isaacs Journal: Prostate Cancer Prostatic Dis Date: 2022-03-28 Impact factor: 5.455
Authors: Burcu F Darst; Raymond Hughley; Aaron Pfennig; Ujani Hazra; Caoqi Fan; Peggy Wan; Xin Sheng; Lucy Xia; Caroline Andrews; Fei Chen; Sonja I Berndt; Zsofia Kote-Jarai; Koveela Govindasami; Jeannette T Bensen; Sue A Ingles; Benjamin A Rybicki; Barbara Nemesure; Esther M John; Jay H Fowke; Chad D Huff; Sara S Strom; William B Isaacs; Jong Y Park; Wei Zheng; Elaine A Ostrander; Patrick C Walsh; John Carpten; Thomas A Sellers; Kosj Yamoah; Adam B Murphy; Maureen Sanderson; Dana C Crawford; Susan M Gapstur; William S Bush; Melinda C Aldrich; Olivier Cussenot; Gyorgy Petrovics; Jennifer Cullen; Christine Neslund-Dudas; Rick A Kittles; Jianfeng Xu; Mariana C Stern; Anand P Chokkalingam; Luc Multigner; Marie-Elise Parent; Florence Menegaux; Geraldine Cancel-Tassin; Adam S Kibel; Eric A Klein; Phyllis J Goodman; Janet L Stanford; Bettina F Drake; Jennifer J Hu; Peter E Clark; Pascal Blanchet; Graham Casey; Anselm J M Hennis; Alexander Lubwama; Ian M Thompson; Robin J Leach; Susan M Gundell; Loreall Pooler; James L Mohler; Elizabeth T H Fontham; Gary J Smith; Jack A Taylor; Laurent Brureau; William J Blot; Richard Biritwum; Evelyn Tay; Ann Truelove; Shelley Niwa; Yao Tettey; Rohit Varma; Roberta McKean-Cowdin; Mina Torres; Mohamed Jalloh; Serigne Magueye Gueye; Lamine Niang; Olufemi Ogunbiyi; Michael Oladimeji Idowu; Olufemi Popoola; Akindele O Adebiyi; Oseremen I Aisuodionoe-Shadrach; Maxwell Nwegbu; Ben Adusei; Sunny Mante; Afua Darkwa-Abrahams; Edward D Yeboah; James E Mensah; Andrew Anthony Adjei; Halimatou Diop; Michael B Cook; Stephen J Chanock; Stephen Watya; Rosalind A Eeles; Charleston W K Chiang; Joseph Lachance; Timothy R Rebbeck; David V Conti; Christopher A Haiman Journal: Eur Urol Date: 2022-01-12 Impact factor: 24.267
Authors: Goutam Chakraborty; Joshua Armenia; Ying Z Mazzu; Subhiksha Nandakumar; Konrad H Stopsack; Mohammad O Atiq; Kazumasa Komura; Lina Jehane; Rahim Hirani; Kalyani Chadalavada; Yuki Yoshikawa; Nabeela A Khan; Yu Chen; Wassim Abida; Lorelei A Mucci; Gwo-Shu Mary Lee; Gouri J Nanjangud; Philip W Kantoff Journal: Clin Cancer Res Date: 2019-12-03 Impact factor: 12.531